TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37847695
Drug: Medication Review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Review with Follow-up (MRF) service
Study: 34677609
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current brain stimulation (tDCS; 2 mA) for 20 minutes before chemotherapy
Study: 36701604
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine
Study: 35354637
Drug: BP self-monitoring
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BP self-monitoring and tele-monitoring plus a free SPC-based telemedicine titration therapy for 6 months
Study: 35354637
Drug: Self-monitoring BP
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-monitoring BP without any therapy change
Study: 35175066
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alcohol condition (BrAC = .04%)
Study: 35175066
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alcohol condition (BrAC = .08%)
Study: 32568433
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (0.5 µg/kg/min)
Study: 35270330
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) continued daily activities without modification
Study: 38939389
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K Antagonist (VKA)
Study: 38286484
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg tenecteplase
Study: 33565715
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (4000 IU daily)
Study: 32073316
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C (1,500 mg per day in three divided doses) from the first postoperative day
Study: 32073316
Drug: Routine postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine postoperative medications with placebo
Study: 35711607
Drug: Auricular plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular plaster therapy (APT)
Study: 36262834
Drug: Sham auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham auricular plaster therapy
Study: 34139038
Drug: Vibegron 50
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibegron 50 mg (V50)
Study: 34139038
Drug: Vibegron 100
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibegron 100 mg (V100)
Study: 33022197
Drug: SKNB19 (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKNB19 (twice a day application)
Study: 35727626
Drug: Unguided IBI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided IBI using cognitive behavior therapy
Study: 35320361
Drug: 80 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 μg dasiglucagon
Study: 35320361
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg dasiglucagon
Study: 38215886
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (10 g)
Study: 34415795
Drug: Topical lotilaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lotilaner ophthalmic solution, 0.25%, treated bid for 42 days
Study: 32275032
Drug: Ketorolac 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 120 mg
Study: 32275032
Drug: Paracetamol 4
Normalized name: Paracetamol 48.2 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 4 g
Study: 36181047
Drug: XGBoost model
Approvals — FDA: no, EMA: no, PMDA: no
Description: XGBoost model with variables related to intravenous (IV) fluid management and electrolytes
Study: 34044245
Drug: Daily antioxidant
Normalized name: Ascorbic Acid/Selenium/Vitamin A/Vitamin E Oral Capsule, Liquid Filled [DAILY ANTIOXIDANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antioxidant supplement comprising polyphenols, omega‐3 fatty acids, vitamin E, and selenium
Study: 32026568
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (LNS) during pregnancy and 6 months postpartum
Study: 34809475
Drug: Temporary basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary basal rate and extended bolus features in addition to basal insulin modifications
Study: 34809475
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin adjustments only
Study: 34420200
Drug: Vitamin-containing amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-containing amino acid supplement (LGA group)
Study: 35966733
Drug: Warm needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needle acupuncture plus Xitong Waixi lotion
Study: 35966733
Drug: Xitong Waixi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xitong Waixi lotion
Study: 33243443
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus EP-100 (80 mg/m2 paclitaxel intravenously plus 30 mg/m2 EP-100 intravenously)
Study: 33243443
Drug: Paclitaxel alone
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel alone (80 mg/m2 intravenously)
Study: 33407801
Drug: upadacitinib 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 7.5 mg QD
Study: 37945286
Drug: upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 15 mg QD
Study: 37945286
Drug: upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 30 mg QD
Study: 33407801
Drug: upadacitinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib (all doses) after switching from placebo
Study: 33407801
Drug: upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 15 mg and 30 mg
Study: 33407801
Drug: upadacitinib 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 7.5 mg and 15 mg
Study: 36383809
Drug: Dexmedetomidine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (bolus 0.5 mcg/kg followed by 0.7 mcg/kg/h)
Study: 33839465
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids and potassium thiocyanate with standard treatment of SCA (test group, N = 14)
Study: 33839465
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only (control group, N = 7)
Study: 33135390
Drug: Lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 10 mg with famotidine
Study: 34412739
Drug: Potential clinically
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential clinically significant drug-drug interactions (DDIs) detected using Lexicomp software
Study: 32583957
Drug: Umibecestat (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umibecestat (orally active β‐secretase inhibitor)
Study: 32240832
Drug: Antibiotics (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (n = 85) for 7 days
Study: 32240832
Drug: Antibiotics (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (n = 85)
Study: 34063455
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (PD-1 and PD-L1 antibodies)
Study: 34193480
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 0.25 mg/kg
Study: 32962684
Drug: Generic cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic cognitive-behavioral therapy self-help in app
Study: 33359106
Drug: Acetaminophen 500-mg
Normalized name: acetaminophen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500-mg tablet 45 minutes before reduction
Study: 35791295
Drug: Intranasal testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal testosterone (NT) 11 mg TID
Study: 35791295
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone cypionate (TC) 200 mg ×2 weeks
Study: 35791295
Drug: Subcutaneous testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous testosterone pellets (TP) 800 mg
Study: 33038531
Drug: Diuretic efficiency
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic efficiency (DE) calculated as net fluid output per 40 mg of furosemide equivalents
Study: 34359097
Drug: Salbutamol 400
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 400 μg
Study: 33098800
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood pressure goal of less than 120 mm Hg)
Study: 33411585
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral methotrexate at a dose of 20 mg/m2 (MTX20)
Study: 33411585
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral methotrexate at a dose of 40 mg/m2 (MTX40)
Study: 38174564
Drug: Immediate antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antihypertensive treatment
Study: 34763950
Drug: HAPIBEV™ vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAPIBEV™ vaccine
Study: 37661535
Drug: Havrix® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix® vaccine
Study: 32885352
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (HDD)
Study: 35364022
Drug: CYD-TDV booster
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD-TDV booster after 1 year (two-dose primary schedule)
Study: 35364022
Drug: CYD-TDV booster
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD-TDV booster after 2 years (two-dose primary schedule)
Study: 34526950
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic conditioning (twice daily for 5 days, blood pressure cuff inflated to 20 mmHg above systolic blood pressure, up to 180 mmHg)
Study: 32347270
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) 1 gram (830 mg of GTP) with quercetin (Q) 800 mg
Study: 38153735
Drug: Behavioral Therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Therapy (BT)
Study: 37619705
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetaminophen and ibuprofen
Study: 33486572
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of 10 g viscous fiber, 60 g white chia seeds, 1.5 g American ginseng, and 0.75 g Korean ginseng extracts
Study: 33486572
Drug: Energy and
Normalized name: Energy And Endurance Testosterone UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy and fiber-matched control (53 g oat bran, 25 g inulin, 25 g maltodextrin, and 2.25 g wheat bran)
Study: 33025690
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg IV acetaminophen
Study: 33332726
Drug: Dexamethasone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.1 mg/kg and 1 mg/kg) for 10 days
Study: 33332726
Drug: Propranolol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (30 mg/kg) as positive control
Study: 33332726
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (10 ml/kg) as negative control
Study: 35094120
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (breathing exercises + manual therapy)
Study: 34256550
Drug: 34 kcal
Normalized name: nut. therapy for PKU, no.49 2 gram-34 kcal/100 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 34 kcal of a fructose solution daily for 5 days
Study: 34256550
Drug: Water for
Normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water for the first 5 days followed by 34 kcal fructose solution
Study: 32057907
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release formulations containing a model drug of BCS class III
Study: 32965655
Drug: Cal/BD foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cal/BD foam applied twice weekly for up to 52 weeks
Study: 32965655
Drug: Foam vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foam vehicle applied twice weekly for up to 52 weeks (control)
Study: 32965655
Drug: Cal/BD foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cal/BD foam (rescue therapy) applied once daily for 4 weeks on active areas
Study: 32965655
Drug: Cal/BD foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cal/BD foam applied twice weekly
Study: 32965655
Drug: Foam vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foam vehicle applied twice weekly (control)
Study: 33423549
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy
Study: 35135323
Drug: Second cohort
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second cohort (endovascular treatment)
Study: 34487920
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 10 J/cm2 plus conventional treatment
Study: 34487920
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 8 J/cm2 plus conventional treatment
Study: 34487920
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 4 J/cm2 plus conventional treatment
Study: 34487920
Drug: Placebo LLLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo LLLT plus conventional treatment
Study: 32323191
Drug: Rivaroxaban (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (twice-daily dosing)
Study: 34559101
Drug: Yijinjing exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yijinjing exercise for 4 months in addition to conventional treatment
Study: 34559101
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with maintained current lifestyle
Study: 32005308
Drug: High-dose aminoglycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aminoglycoside group (≥75 mg/kg/week)
Study: 33301738
Drug: Oral panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral panobinostat 20 mg three times weekly
Study: 33301738
Drug: Oral panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral panobinostat 20 mg twice weekly
Study: 33301738
Drug: Oral panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral panobinostat 10 mg three times weekly
Study: 36207474
Drug: AI/ML-based CAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI/ML-based CAD devices for detection of colorectal polyps
Study: 36207474
Drug: Standalone software
Normalized name: sandalore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standalone software testing for AI/ML-based CAD devices
Study: 36268789
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg (maximum of 5 mg) of dexamethasone diluted to a total volume of 2 ml with 0.9% saline (n = 50)
Study: 36268789
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 0.9% saline (n = 50)
Study: 36268789
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg (maximum of 5 mg) of dexamethasone
Study: 33151802
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow aspirate concentrate injections via superolateral, anteromedial or anterolateral portals
Study: 33548338
Drug: Elevated or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated or increasing neutrophil count after induction chemotherapy
Study: 34688915
Drug: Individualized Postural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized Postural Therapy (IPT)
Study: 33558215
Drug: Rectal and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal and axillary temperature measurements
Study: 35331432
Drug: Vein of
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein of Marshall ethanol infusion (VOMEt) as first step preceding RF ablation (VOMFIRST group)
Study: 34781656
Drug: Subcutaneous Pegylated
Normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Pegylated erythropoietin at a dose of 0.6 mcg/kg body weight, once every two weeks along with intravenous iron 100 mg/week for 3 months.
Study: 34781656
Drug: Subcutaneous darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous darbepoetin alfa at a dose of 0.45 mcg/kg body weight once weekly along with intravenous iron 100 mg/week for 3 months.
Study: 34114138
Drug: Brinzolamide-brimonidine fixed
Normalized name: brimonidine / brinzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide-brimonidine fixed combination (1 drop, instilled 2 hours before injection)
Study: 34114138
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylactic medication)
Study: 33690610
Drug: Standard nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard nevirapine syrup
Study: 32501994
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (heat-clearing and detoxifying Chinese medicines combined with conventional therapy)
Study: 32501994
Drug: Jinlianqingre effervescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinlianqingre effervescent tablets (part of combination therapy)
Study: 37079268
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group (App + usual care)
Study: 32346959
Drug: TAZ/BM cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAZ/BM cream
Study: 32346959
Drug: TAZ gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAZ gel
Study: 32346959
Drug: BM cream
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BM cream
Study: 35092347
Drug: Amlodipine and
Normalized name: amlodipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine and chelation therapy
Study: 35092347
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy only
Study: 34919248
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline solution (NSS)
Study: 35979636
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin
Study: 32247530
Drug: Mindfulness and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness and self-care program consisting of 9 weekly sessions of 90min, daily practice, and reinforcement sessions at 1 month, 3, 6, and 12 months.
Study: 34418414
Drug: Incremental hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incremental hemodialysis (twice‐weekly sessions, upwardly adjusting hemodialysis dose)
Study: 34418414
Drug: Standard hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hemodialysis (thrice weekly for 3.5‐4 hours, minimum Dialysis Std Kt/V of 2)
Study: 35149233
Drug: Trofinetide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofinetide (200 mg/kg twice daily)
Study: 35149233
Drug: Trofinetide (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofinetide (50, 100, and 200 mg/kg BID)
Study: 35705139
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg orally per day for 12 weeks)
Study: 32658830
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus treatment as usual (TAU)